NO20010569L - Proteaseinhibitorer for anvendelse ved behandling av psoriasis - Google Patents

Proteaseinhibitorer for anvendelse ved behandling av psoriasis

Info

Publication number
NO20010569L
NO20010569L NO20010569A NO20010569A NO20010569L NO 20010569 L NO20010569 L NO 20010569L NO 20010569 A NO20010569 A NO 20010569A NO 20010569 A NO20010569 A NO 20010569A NO 20010569 L NO20010569 L NO 20010569L
Authority
NO
Norway
Prior art keywords
protease inhibitors
psoriasis
treatment
inhibitors
pai
Prior art date
Application number
NO20010569A
Other languages
English (en)
Other versions
NO20010569D0 (no
Inventor
Clive Leighton Bunn
Phillip John Sharp
Original Assignee
Biotech Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotech Australia Pty Ltd filed Critical Biotech Australia Pty Ltd
Publication of NO20010569D0 publication Critical patent/NO20010569D0/no
Publication of NO20010569L publication Critical patent/NO20010569L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Psoriasis kan behandles ved topisk administrering av en urokinaseinhibi- tor, slik som PAI-2, eller en kombi- nasjon av proteaseinhibitorer, slik som PAI-2, sammen med andre serinprotease- inhibitorer og/eller med protease- inhibitorer, slik som inhibitorer av metallproteinasaer, sure protesaer og tiolproteaser.
NO20010569A 1998-08-05 2001-02-02 Proteaseinhibitorer for anvendelse ved behandling av psoriasis NO20010569L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP5087A AUPP508798A0 (en) 1998-08-05 1998-08-05 Method of treating psoriasis
PCT/IB1999/001483 WO2000007620A1 (en) 1998-08-05 1999-08-05 Protease inhibitors for use in the treatment of psoriasis

Publications (2)

Publication Number Publication Date
NO20010569D0 NO20010569D0 (no) 2001-02-02
NO20010569L true NO20010569L (no) 2001-04-04

Family

ID=3809320

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010569A NO20010569L (no) 1998-08-05 2001-02-02 Proteaseinhibitorer for anvendelse ved behandling av psoriasis

Country Status (10)

Country Link
US (1) US6288025B1 (no)
EP (1) EP1102599A4 (no)
JP (1) JP2002522396A (no)
KR (1) KR20010072278A (no)
CN (1) CN1322138A (no)
AU (1) AUPP508798A0 (no)
CA (1) CA2339485A1 (no)
IL (1) IL141056A0 (no)
NO (1) NO20010569L (no)
WO (1) WO2000007620A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ380699A0 (en) * 1999-11-02 1999-11-25 Biotech Australia Pty Limited Protease inhibitors as modulators of periodontal wound healing
DE60328909D1 (de) * 2002-11-20 2009-10-01 Arriva Prometic Inc Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin
SE531785C2 (sv) * 2006-12-05 2009-08-04 Bengt-Sture Ershag Anläggning för återvinning av kol och kolväteföreningar genom pyrolys
WO2009026949A1 (en) * 2007-08-31 2009-03-05 Dsm Ip Assets B.V. 4-amidino benzylamines for cosmetic and/or dermatological use
CN110522905A (zh) 2008-01-21 2019-12-03 德莫迪斯公司 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途
US10377818B2 (en) 2015-01-30 2019-08-13 The Board Of Trustees Of The Leland Stanford Junior University Method of treating glioma

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290762A (en) * 1986-12-24 1994-03-01 John Lezdey Treatment of inflammation
DE3829523A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von plasminogen-aktivator-inhibitor (pai-2) zur immunsuppression
EP1029921B1 (en) 1989-03-06 2002-10-23 The Board of Regents of The University of Texas System Serpin resistant t-PA; mutants; genes
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
US5550042A (en) 1989-03-06 1996-08-27 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors and genes encoding the same and serine protease inhibitor mutants and genes encoding the same
CA2021660A1 (en) 1989-07-26 1991-01-27 Philippe Bey Peptidase inhibitors
ATE154362T1 (de) 1989-09-05 1997-06-15 Biotech Australia Pty Ltd Verfahren zur herstellung von pai-2
US5204807A (en) 1989-10-04 1993-04-20 Pitney Bowes Plc. Postage meter housing arrangement having RF and electromagnetic induction shielding
JP2567536B2 (ja) 1989-12-20 1996-12-25 バイオテック オーストラリア プロプライアタリィ リミティド Ｐａｉー２の変異体
US5242801A (en) 1990-08-06 1993-09-07 University Of Iowa Research Foundation Diagnosing malignant hyperthermia susceptibility by detection of abnormal proteolytic enzyme digestion fragments of the ryanodine receptor
JPH06279316A (ja) 1993-03-25 1994-10-04 Shiseido Co Ltd 皮膚外用剤
US5403482A (en) 1993-10-12 1995-04-04 Gelman Sciences Inc. Self-supporting, pleated, spirally wound filter and the corresponding process of making
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
US5618792A (en) * 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
US5939525A (en) * 1995-03-27 1999-08-17 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
CN1299286A (zh) 1998-04-01 2001-06-13 澳洲生物科技公司 应用蛋白酶抑制剂治疗皮肤伤口

Also Published As

Publication number Publication date
WO2000007620A1 (en) 2000-02-17
NO20010569D0 (no) 2001-02-02
IL141056A0 (en) 2002-02-10
CA2339485A1 (en) 2000-02-17
US6288025B1 (en) 2001-09-11
JP2002522396A (ja) 2002-07-23
CN1322138A (zh) 2001-11-14
KR20010072278A (ko) 2001-07-31
EP1102599A4 (en) 2004-03-17
AUPP508798A0 (en) 1998-08-27
EP1102599A1 (en) 2001-05-30

Similar Documents

Publication Publication Date Title
ATE307111T1 (de) Serinprotease-inhibitoren
DE69635447D1 (de) Plasma-kallikrein inhibitoren vom kunitz-typ
IL158559A0 (en) Acne treatment
IL222773A0 (en) Biaryl compounds as serine protease inhibitors pharmaceutical compostions, uses, in vitro methods and devices comprising such compounds
DK1071417T3 (da) Anvendelse af cannabidiol som anti-inflammatorisk middel
MXPA03009130A (es) Compuestos de biarilo que funcionan como inhibidores de proteasa serina.
ATE234117T1 (de) Verwendung des sekretorischen leukozytaren protease inhibitors (slpi) als tryptase-inhibitor
DK1272154T3 (da) Præparat til forbedring af hudlipidbarrierefunktionen
ATE439853T1 (de) Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin
NZ507050A (en) Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors
WO1998022098A3 (en) Cpp32 inhibitors for regulating apoptosis
DE60026279D1 (de) Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
EP1032393A4 (en) QUINOLIN-CONTAINING ALPHA-KETOAMIDE-BASED INHIBITORS OF CYSTEIN AND SERINE PROTEASE
WO2002060869A3 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
BR9815469A (pt) Inibidores de protease
EP0297597A3 (en) Method for determining the activity of serine proteinases or serine proteinase inhibitors
NO20010569L (no) Proteaseinhibitorer for anvendelse ved behandling av psoriasis
ATE131066T1 (de) Mittel zur hemmung von hiv-proteasen.
NO20004920L (no) Anvendelse av proteaseinhibitorer for behandling av hudsår
AR021241A1 (es) Inhibidores de proteasas
MY132033A (en) New mandelic acid derivatives and their use as thrombin inhibitors
TR200000954T2 (tr) Mikrodolaşım hastalıklarının tedavisi ve önlenmesi için madde.
EA200301130A1 (ru) Применение ингибиторов протеазы вируса иммунодефицита человека (вич) для блокирования миграции клеток и/или инвазии, инфильтрации тканей и отека при лечении связанных с этим заболеваний
DK0666841T3 (da) Succinoylamino-hydroxyethylaminosulfaminsyrederivater til anvendelse som inhibitorer af retrovirale proteaser
IS7162A (is) Nýjar möndlusýruafleiður og notkun þeirra sem þrombínhemla

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application